Hubert C. Chen - 25 Feb 2023 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)

Role
President and Chief Scientific Officer
Signature
/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Issuer symbol
FBRX
Transactions as of
25 Feb 2023
Net transactions value
$0
Form type
4
Filing time
27 Feb 2023, 19:15:42 UTC
Previous filing
08 Jun 2022
Next filing
04 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FBRX Restricted Stock Units Award $0 +120,000 $0.000000 120,000 25 Feb 2023 Common Stock 120,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock.
F2 Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.

Remarks:

President and Chief Scientific Officer